In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance.

ABSTRACT: Many drugs are effective in the early stage of treatment, but patients develop drug resistance after a certain period of treatment, causing failure of the therapy. An important example is Herceptin, a popular monoclonal antibody drug for breast cancer by specifically targeting human epidermal growth factor receptor 2 (Her2). Here we demonstrate a quantitative binding kinetics analysis of drug-target interactions to investigate the molecular scale origin of drug resistance. Using a surface plasmon resonance imaging, we measured the in situ Herceptin-Her2 binding kinetics in single intact cancer cells for the first time, and observed significantly weakened Herceptin-Her2 interactions in Herceptin-resistant cells, compared to those in Herceptin-sensitive cells. We further showed that the ster

SUBMITTER: Wang W 

PROVIDER: S-EPMC4196117 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature